- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| POLARYX THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.09. | Polaryx appoints Will Charlton as chief medical officer | 1 | Investing.com | ||
| 01.09. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Appoints Dr. Will Charlton as Chief Medical Officer | 145 | GlobeNewswire (Europe) | Dr. Charlton brings over 15 years of rare disease and pediatric drug development experience including CMO and clinical development roles Appointment further strengthens clinical leadership and execution... ► Artikel lesen | |
| 13.08. | Raymond James initiates Polaryx Therapeutics stock with strong buy | 1 | Investing.com | ||
| 13.08. | Raymond James startet Coverage für Polaryx Therapeutics mit "Strong Buy" und sieht 170 % Kurspotenzial | 10 | Investing.com Deutsch | ||
| 27.07. | Lucid Capital startet Coverage für Polaryx mit Kaufempfehlung - Potenzial bei Therapie für seltene Krankheiten | 1 | Investing.com Deutsch | ||
| 27.07. | Lucid Capital initiates Polaryx stock with buy rating on rare disease therapy potential | 2 | Investing.com | ||
| 24.07. | Polaryx Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 17.07. | Polaryx Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 03.07. | XFRA NEW INSTRUMENTS AVAILABLE ON 03.07.2026 | 602 | Xetra Newsboard | The following instruments on XETRA do have their first trading 03.07.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 03.07.2026
Aktien
1 JP3100020001 Archion Corp.
2 US73110F1003... ► Artikel lesen | |
| 28.05. | Polaryx Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | Polaryx Therapeutics sichert sich 10 Millionen US-Dollar über PIPE-Finanzierung | 1 | Investing.com Deutsch | ||
| 28.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Closing of $10 Million Private Placement Equity Financing to Support Launch of SOTERIA Phase 2 Basket Trial | 1 | GlobeNewswire (USA) | ||
| 14.05. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives GHP Magazine's Healthcare & Pharmaceuticals Awards | 4 | GlobeNewswire (USA) | ||
| 21.04. | FDA grants fast track status to Polaryx's PLX-200 for three rare diseases | 2 | Investing.com | ||
| 21.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket Trial | 393 | GlobeNewswire (Europe) | PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics, Inc. (Nasdaq: PLYX), a clinical-stage biotechnology company developing disease-modifying therapies for rare pediatric LSDs,... ► Artikel lesen | |
| 15.04. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric Care | 1 | GlobeNewswire (USA) | ||
| 17.03. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Receives FDA Fast Track Designation for PLX-200 for Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) | 318 | GlobeNewswire (Europe) | Regulatory milestone supports advancement of the SOTERIA Phase 2 basket trial evaluating PLX-200 across multiple lysosomal storage disorders PARAMUS, NJ, March 17, 2026 (GLOBE NEWSWIRE) -- Polaryx... ► Artikel lesen | |
| 17.02. | Morning Market Movers: Polaryx Therapeutics, JIADE, ZIM Integrated Shipping Services, Masimo Corporation See Big Swings | 980 | AFX News | WASHINGTON (dpa-AFX) - At 7:05 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| 02.02. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol "PLYX" | 412 | GlobeNewswire (Europe) | PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen | |
| 30.01. | Polaryx Therapeutics, Inc.: Polaryx Therapeutics Announces Approval to List Common Stock on Nasdaq | 330 | GlobeNewswire (Europe) | PARAMUS, NJ, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,905 | +0,41 % | Valneva-Aktie: Analysten sehen über +150% Potenzial | Bei Valneva ist wieder ordentlich Bewegung drin. Gestern legte die Aktie um +6,45% auf 2,99 € zu und gehörte damit zu den stärksten Werten am französischen Aktienmarkt. Eine neue Unternehmensmeldung... ► Artikel lesen | |
| PALATIN TECHNOLOGIES | 12,220 | -0,89 % | Wall Street Wire: StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It | Rare-endocrine buyers have paid roughly $2.9 billion and approximately $10.0 billion for acquisitions in this area over the past four months. IMCIVREE, the only approved MC4R agonist for acquired... ► Artikel lesen | |
| OCUGEN | 0,970 | +5,55 % | Ocugen slips after interim trial data for Stargardt disease candidate | ||
| VIVORYON THERAPEUTICS | 1,130 | 0,00 % | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026 | Vivoryon Therapeutics N.V. to Hold its 2026 Annual General Meeting on September 29, 2026
Halle (Saale) / Munich, Germany, August 18, 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7)... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 19,040 | +0,63 % | Sarepta Therapeutics climbs 10%, rebounding from recent slide | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,082 | -2,13 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,693 | 0,00 % | RedHill Biopharma Ltd.: RedHill Divests Talicia to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities | Executes a major step in RedHill's strategic roadmap to fundamentally reposition the Company's commercial business toward new and larger product opportunities, revenue growth and an accelerated... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 9,550 | -3,54 % | Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs | ||
| VERASTEM | 6,742 | -1,32 % | Verastem Stock Skyrockets 121% in 3 Months: Here Is Why | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,844 | -0,16 % | Oxford Nanopore Tech - Participation in upcoming investor conferences | ||
| ROCKET PHARMACEUTICALS | 3,060 | -1,92 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,872 | +2,94 % | Voyager Therapeutics, Inc.: Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 | - Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging... ► Artikel lesen | |
| PALISADE BIO | 2,050 | 0,00 % | Palisade Bio, Inc.: Palisade Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Advancement of PALI-2108 Into Phase 2 Development | Advancing a potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug specifically engineered for the treatment of inflammatory bowel disease (IBD) Enrollment of first patient... ► Artikel lesen | |
| XBIOTECH | 1,722 | -5,18 % | XBiotech Inc.: XBiotech startet klinische Phase-II-Studie zur Bewertung von Vilamakitug bei der Behandlung der aktiven axialen Spondyloarthritis | Der IND-Antrag für die V-SPINE-Studie hat die 30-tägige FDA-Prüfung ohne klinischen Stopp durchlaufen und ebnet damit den Weg für die Aufnahme von Patienten in den USAAUSTIN, Texas, June 15, 2026 (GLOBE... ► Artikel lesen | |
| PERSONALIS | 13,700 | -2,94 % | XFRA 04X: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
Das Unternehmen POLARYX THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,034 (+2,04 %) liegt der Kurs bei 1,698 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLARYX THERAPEUTICS INC finden Sie auf Wallstreet Online.